FMTDNAT-Cologuard was designed to detect human hemoglobin (i.e., like FIT) plus detection of mutations associated with CRC in the DNA of cells shed by advanced adenomas or CRC (quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, and β-actin, plus a hemoglobin immunoassay) [7,20]. This evidence concerns the gene BMP3 and colorectal carcinoma.